Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles Craddock

Showing results (141-150 of 165) with videos related to

Pageof 17
Sort By:
Blood|July 7, 2022
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELNHartmut Döhner, Andrew H Wei, Frederick R Appelbaum, et al.
Annals of Hematology|April 18, 2019
The prognostic impact of the cytomegalovirus serostatus in patients with chronic hematological malignancies after allogeneic hematopoietic stem cell transplantation: a report from the Infectious Diseases Working Party of EBMTMartin Schmidt-Hieber, Gloria Tridello, Per Ljungman, et al.
Haematologica|January 19, 2019
Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantationNico Gagelmann, Diderik-Jan Eikema, Matthias Stelljes, et al.
Bone Marrow Transplantation|December 1, 2023
Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working PartyJesús Duque-Afonso, Jürgen Finke, Maud Ngoya, et al.
Blood|August 12, 2024
Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendationsHartmut Döhner, Courtney D DiNardo, Frederick R Appelbaum, et al.
Science Translational Medicine|September 20, 2013
MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemiaMark Cobbold, Hugo De La Peña, Andrew Norris, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 7, 2016
Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant ResearchVictoria T Potter, Simona Iacobelli, Anja van Biezen, et al.
Haematologica|January 19, 2019
Antilymphocyte globulin for matched sibling donor transplantation in patients with myelofibrosisMarie Robin, Sylvie Chevret, Linda Koster, et al.
Bone Marrow Transplantation|December 4, 2025
Frequency and impact of somatic co-occurring mutations on post-transplant outcomes in acute myeloid leukemia: a multicenter registry analysis on behalf of the EBMT ALWPAli Bazarbachi, Jacques-Emmanuel Galimard, Iman Abou Dalle, et al.
Bone Marrow Transplantation|March 27, 2020
Reducing the diversity of allogeneic transplant protocols in the UK through a BSBMT Anthony Nolan Protocol Harmonization InitiativeChloe Anthias, Jane Apperley, Adrian Bloor, et al.
Pageof 17

Showing results (141-150 of 165) with videos related to

Sort By:
Pageof 17
Blood|July 7, 2022
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELNHartmut Döhner, Andrew H Wei, Frederick R Appelbaum, et al.
Annals of Hematology|April 18, 2019
The prognostic impact of the cytomegalovirus serostatus in patients with chronic hematological malignancies after allogeneic hematopoietic stem cell transplantation: a report from the Infectious Diseases Working Party of EBMTMartin Schmidt-Hieber, Gloria Tridello, Per Ljungman, et al.
Haematologica|January 19, 2019
Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantationNico Gagelmann, Diderik-Jan Eikema, Matthias Stelljes, et al.
Bone Marrow Transplantation|December 1, 2023
Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working PartyJesús Duque-Afonso, Jürgen Finke, Maud Ngoya, et al.
Blood|August 12, 2024
Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendationsHartmut Döhner, Courtney D DiNardo, Frederick R Appelbaum, et al.
Science Translational Medicine|September 20, 2013
MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemiaMark Cobbold, Hugo De La Peña, Andrew Norris, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 7, 2016
Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant ResearchVictoria T Potter, Simona Iacobelli, Anja van Biezen, et al.
Haematologica|January 19, 2019
Antilymphocyte globulin for matched sibling donor transplantation in patients with myelofibrosisMarie Robin, Sylvie Chevret, Linda Koster, et al.
Bone Marrow Transplantation|December 4, 2025
Frequency and impact of somatic co-occurring mutations on post-transplant outcomes in acute myeloid leukemia: a multicenter registry analysis on behalf of the EBMT ALWPAli Bazarbachi, Jacques-Emmanuel Galimard, Iman Abou Dalle, et al.
Bone Marrow Transplantation|March 27, 2020
Reducing the diversity of allogeneic transplant protocols in the UK through a BSBMT Anthony Nolan Protocol Harmonization InitiativeChloe Anthias, Jane Apperley, Adrian Bloor, et al.
Pageof 17